Patent: 9,550,826
✉ Email this page to a colleague
Summary for Patent: 9,550,826
Title: | Glycoengineered binding protein compositions |
Abstract: | Provided are glycoengineered populations of Fc domain-containing binding proteins with a reduced anti-drug immune response (ADA). Also provided are methods of treating disease using such compositions, and methods and host for making such compositions. |
Inventor(s): | Labkovsky; Boris (Marlborough, MA), Ghayur; Tariq (Holliston, MA), Gaza-Bulseco; Georgeen (Princeton, MA), Mishra; Pratibha (Shrewsbury, MA), Hegde; Subramanya (Shrewsbury, MA), Krishnan; Sudha (Acton, MA) |
Assignee: | AbbVie Inc. (North Chicago, IL) |
Application Number: | 15/198,696 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,550,826 |
Patent Claims: | see list of patent claims |
Details for Patent 9,550,826
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 12/31/2002 | ⤷ Try a Trial | 2033-11-15 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 02/21/2008 | ⤷ Try a Trial | 2033-11-15 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 04/24/2013 | ⤷ Try a Trial | 2033-11-15 |
Abbvie Inc. | HUMIRA | adalimumab | Injection | 125057 | 09/23/2014 | ⤷ Try a Trial | 2033-11-15 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |